Summit Therapeutics Inc (SMMT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$17.61+2.80%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SMMT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | — | — | 0.0 | 0.7 | 1.8 | 0.9 |
| Operating Expenses & Income | |||||||
| R&D Expenses | — | — | — | 59.5 | 52.0 | 85.4 | 53.3 |
| Other Operating Expenses, Total | — | — | 0.3 | 1.0 | 14.4 | — | — |
| Operating Income | — | — | (226.0) | (609.7) | (72.1) | (86.2) | (53.2) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | — | 8.7 | — | 4.4 | 0.2 | 0.3 |
| Interest & Investment Income | 18.9 | 15.5 | 13.5 | 10.4 | 1.5 | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | — | 2.9 | 0.2 | 0.3 |
| Other Non-Operating Income / Expenses | 18.8 | 14.8 | 13.4 | 11.2 | (2.3) | (2.4) | 0.3 |
| EBT, Incl. Unusual Items | — | (1,079.6) | (221.3) | (614.9) | (78.8) | (88.6) | (52.9) |
| Income Tax Expense | — | — | — | 0.0 | — | 0.0 | (0.2) |
| Net Income | |||||||
| Net Income | (856.1) | (1,079.6) | (221.3) | (614.9) | (78.8) | (88.6) | (52.7) |
| Per Share | |||||||
| Basic EPS | (1.10) | (1.44) | (0.31) | (0.99) | (0.41) | (0.67) | (0.76) |
| Diluted EPS | (1.10) | (1.44) | (0.31) | (0.99) | (0.41) | (0.67) | (0.76) |
| Basic Weighted Avg Shares | 778.2 | 747.7 | 718.5 | 619.6 | 193.3 | 131.7 | 69.5 |
| Diluted Weighted Avg Shares | 778.2 | 747.7 | 718.5 | 619.6 | 193.3 | 131.7 | 69.5 |
| Supplemental | |||||||
| EBIT | — | — | (226.0) | (609.7) | (72.1) | (86.2) | (53.2) |
| Effective Tax Rate | — | — | — | 0.0% | — | 0.0% | 0.4% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.